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Alternatively, preventive strategies are available to manage chronic kidney disease before 
symptoms develop.  There are several markers available for testing which allow detection of 
renal damage at earlier stages.  Effective therapies to slow progression of chronic kidney 
disease to end-stage disease are available.  In this study, we investigated the cost-
effectiveness of a screening program for proteinuria among people aged 25-79 when they visit 
a general practitioner for another reason.  We separately consider people with and without 
diabetes mellitus.  The initial screening is by a urine dipstick to detect protein in the urine.  
Those testing positive are subsequently given a confirmatory test (protein-creatinine ratio) and 
an ultrasound of the kidneys and a full blood examination.  Subsequent life-long therapy with 
angiotensin-converting enzyme (ACE) inhibitor is then provided to people identified with 
chronic kidney disease (Figure 1).  We also take into account that ACE-inhibitors have a 
protective effect on ischemic heart disease and stroke. 






We compare the interv ntion with a scenario without the intervention, since there is currently 
no policy of screening for proteinuria in Australia. 
 
4. Intervention cost-effectivenes  
Renal replacement therapy 
All three benchmarks fall in the north-east (‘health gain at a cost’) quadrant of the cost-
effectiveness plane (Figure 2).  Specifically, when comparing the current program to dialysis 
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Table 1  Cost-effectiveness ratios and probability of being cost-effective (renal 
replacement therapy) 
 
Benchmark Cost per DALY (95% uncertainty range) 
Probability of being 
< AUD50,000/DALY 
Current program compared to no treatment 70,000 (65,000 – 76,000) 0% 
Dialysis only compared to no treatment 103,000 (91,000 – 118,000) 0% 
Current program compared to dialysis only 23,000 (20,000 – 26,000) 100% 
 
Figure 2: Cost-effectiveness of the intervention for different benchmark  illustrated on a cost-effectiveness plane 
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Screening and early treatment 
Table 2 provides the ICER and the probabilities of being cost-effective.  The intervention 
targeting different age-groups fall in the north-east (‘health gain at a cost’) or south-east 
(‘health gain and net cost saving’) quadrants of the cost-effectiveness plane (Figure 3).  
Targeting people with diabetes mellitus and those aged 50 years and over have 100% 
probability of being cost-effective.  Net cost-savings would be achieved by focusing on people 
with diabetes mellitus aged 50 and over.  Targeting people without diabetes mellitus over the 
age of 50 is cost-effective, but the probability of a cost-effective resultdecreases to 89% and 
52% for people in the age groups of 40-49 and 25-39, respectively. 
 
Table 1  Cost-effectiveness ratios and probability of being cost-effective (renal 
replacement therapy) 
 
Benchmark Cost per DALY (95% uncertainty range) 
Probability of being 
< AUD50,000/DALY 
Current program compared to no treatment 70,000 (65,000 – 76,000) 0% 
Dialysis onl  compared to no treatment 103,  1,0 0 – 18, 00) 0% 
Current program compared to dialysis only 23,000 (20,000 – 26,000) 100% 
 
 





















Table 2: Cost-effectiveness ratio  and probability of being cost-effective (screening and early 




Cost per DALY 
(95% uncertainty range) 
Probability of being 
< AUD50,000/DALY 
Diabetes mellitus   
50-79 Dominant* (Dominant – 8,000) 100% 
40-49 4,000 (Dominant – 18,000) 100% 
25-39 8,000 (1,000 – 25,000) 100% 
Non-diabetes mellitus   
50-79 12,000 (Dominant – 38,000) 100% 
40-49 33,000 (15,000 – 63,000) 89% 
25-39 49,000 (27,000 – 89,000) 52% 
* Dominant means the cost-effectiveness ratio falls in the south-east quadrant, where more benefits can be accrued at a 
lower cost (i.e. health gain with cost saving). 
 
Figure 3: Cost-effectiveness of the intervention for different target populations illustrated on a 
cost-effectiveness plane with AU$ 50,000 per DALY threshold line (screening and early 
treatment of chronic kidney disease) 




Maintenance dialysis is so expensive that few individuals can afford treatment out of pocket. 
Thus, the provision of renal replacement therapy by the government as a third-party funder 
has the potential to reduce inequalities. Provision of renal replacement therapy on a national 
scale is already current practice. However, the high cost associated with delivering dialysis 
therapy may hinder such an intervention from being sustainable. 
Economists invoke the ‘rule of rescue’ if there is a high-cost but life-saving intervention to a 
small number of individuals even if it would not otherwise be recommended based on cost-
effectiveness. The rule of rescue may be considered relevant to renal dialysis for patients with 
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5. Conclu ions 
Maintenance dialysis is so expensive that few individuals can afford treatment out of pocket. 
Thus, the provision of renal r placement therapy by the gov rnment s a third-party funder 
has the pot ntial to reduce nequaliti s. Prov sion of renal replacement therapy on a national 
scale is already current practice. However, the high cost associated with delivering dialysis 
therapy may hin er such an interve tion from being sustainable. 
Economists invoke the ‘rule of rescue’ if there is a high-cost but life-saving intervention to a 








































14. Renal replacement therapy, screening and early  
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